Articles tagged with Glioblastomas
The study enrolled 237 patients with recurrent GBM and found that NovoTTF was as effective as the best available chemotherapies without the toxicity. Patients treated with NovoTTF lived longer and experienced fewer infections compared to chemotherapy.
A new drug, PD-0332991, has been found to effectively block the growth of glioblastoma cells in laboratory tests and animal studies. The agent targets specific molecules that drive cell division in cancer cells, offering a potential new treatment option for this deadly form of brain cancer.
Researchers at Stanford University School of Medicine found that blocking blood vessel formation prevents brain tumor recurrence in mice. Disrupting the SDF-1/CXCR4 interaction prevented tumor regrowth by abrogating functional tumor vasculature.
Researchers at Stanford University School of Medicine have found that disrupting the SDF-1/CXCR4 interaction can prevent the recruitment of vasculogenic cells to the tumor site, blocking postirradiation development of functional tumor vasculature and tumor regrowth. This approach may be applicable to treating glioblastoma multiforme.
The Cancer Genome Atlas reveals four molecular subtypes of glioblastoma multiforme (GBM), the most common form of malignant brain cancer in adults. Researchers found that response to chemotherapy and radiation differed by subtype, with some subtypes experiencing a 50% slower disease progression.
Researchers at UNC Lineberger Comprehensive Cancer Center identified four distinct molecular subtypes of GBM, each associated with a specific disease process. The study provides a solid framework for investigation of future targeted therapies that may improve the prognosis of this devastating cancer.
Researchers from M.D. Anderson Cancer Center discovered that cancer stem cells inhibit T cell response and evade immune attack on glioblastoma multiforme. Differentiation of these cells into other neural types can restore the immune response, offering new hope for treatment.
Researchers have identified two genes, C/EPB and Stat3, which are responsible for the most aggressive forms of human brain cancer. These genes work together to transform normal brain cells into highly aggressive cells, making them a major target for new treatments.
Researchers at the University of Central Florida have found a protein, TRPC6, that could hold the key to treating GBM, a type of malignant brain tumor. Knocking down this protein's expression can stop tumor growth and spread.
Researchers at University Hospitals Case Medical Center report promising results from a study treating glioblastoma multiforme with Gamma Knife radiosurgery, increasing patient survival rates by almost four months compared to traditional radiotherapy alone.
A Phase II study shows Avastin significantly increases response rates, progression-free survival times and survival rates in patients with recurrent glioblastoma. The treatment was found to be effective both alone and in combination with chemotherapy, improving patient outcomes and quality of life.
Researchers funded by NIH have found a key factor in the spread of aggressive brain cancer glioblastoma multiforme (GBM). A small designer protein can block the activity of a protein fragment that stimulates GBM cell migration, suggesting a potential new therapy target.
Researchers found that STAT3 inhibits the growth and self-renewal of glioblastoma stem cells, suggesting a promising target for cancer therapy. The study demonstrates the potential of STAT3 inhibitors to stop tumor formation and offers a new approach to treating this devastating brain cancer.
Glioblastoma, the deadliest form of brain cancer, has shown promise in treating with an engineered antibody that shuts down tumor growth. Researchers at Lombardi Comprehensive Cancer Center successfully tested the antibody in human cells and animal studies.
A network of 31 mutated genes has been identified as the driving force behind glioblastoma growth. Annexin A7, a vital guard gene, is lost in most cases, allowing tumors to flourish. The discovery offers new therapeutic targets and potentially extends patient survival.
Recent JAMA studies on brain cancer and altered genes have made significant progress in understanding the root causes of this deadly disease. Researchers identified seven genes linked to survival among glioblastoma multiforme patients, paving the way for potential new therapies.
Researchers at UNC School of Medicine have identified a compound that could treat secondary glioblastoma multiforme (GBM), a type of brain tumor. By replenishing α-ketoglutarate, they reversed the effects of IDH1 gene mutation, which contributes to tumor growth.
Researchers at Duke University have identified a receptor on human glioblastoma cells that may be an appropriate target for therapies. Activation of the neurokinin 1 receptor leads to increased cell growth, but blocking this activity can reduce cell death and potentially stall cancer growth.
Researchers at UT Southwestern Medical Center have identified a new biological indicator, RIP1, that may help identify the most aggressive forms of adult brain cancer. High levels of RIP1 are commonly found in glioblastoma tumors and are associated with poor prognosis and resistance to chemotherapy.
The study found that treatment with cediranib reduced edema and improved survival in mice with glioblastoma tumors. Mice receiving the drug lived significantly longer than controls, despite continued tumor growth.
The EORTC-NCIC trial found that adding chemotherapy to radiotherapy significantly increases survival in glioblastoma patients, with improved outcomes seen across all clinical prognostic subgroups. The study suggests testing tumour MGMT gene methylation status to identify patients most likely to benefit from this treatment.
Researchers at Bonn University discovered a critical improvement in treating glioblastoma, the most aggressive and common brain tumor. The combination of two drugs increased average survival time to 23 months, with some patients surviving over four years. Further investigations are needed to optimize this therapy.
Scientists at Duke University Medical Center and Johns Hopkins University have identified two genes with potential as therapeutic targets for malignant glioma, a deadly class of brain tumors. IDH1 mutations were found in over 70% of astrocytomas and olidgodendrogliomas, associated with longer survival times.
Scientists have identified two gene mutations, IDH1 and IDH2, linked to nearly three-quarters of gliomas, a type of brain cancer. These mutations are associated with longer survival rates in patients with certain types of gliomas. Further research may lead to more precise diagnoses and treatments.
A study found that elderly patients with glioblastoma are less likely to undergo surgery, radiation, or chemotherapy due to concerns about toxic side effects. The median survival for these patients was only four months.
Researchers have identified a mechanism for an effective immune response to brain tumors by combining immunotherapy and strategies to kill tumor cells. The study suggests that this combination may provide effective treatment for glioblastoma multiforme, the most aggressive form of brain cancer.
The Novo-TTF device was shown to enhance the efficacy of standard chemotherapy in treating newly-diagnosed glioblastoma multiforme patients. Combination therapy with the device prolonged time to disease progression by nearly 31 months and increased survival by more than 25 months compared to historical results.
A family history of brain tumors is linked to a higher risk of developing the same type of tumor. Researchers found that people with immediate relatives who suffered from glioblastomas or astrocytomas were nearly four and twice as likely to contract the same kind of brain cancer, respectively.
The Cancer Genome Atlas reports findings on the MGMT gene, which makes brain cancer cells more responsive to treatment but also leads to mutations in other genes essential for DNA repair. These mutations contribute to cancer recurrence and resistance to treatment.
A large-scale study has identified a range of genetic mutations and signaling pathways disrupted in glioblastoma, the most common adult brain cancer. The findings validate the potential of unbiased genome analysis to lead to paradigm-shifting discoveries and identify new targets for treatment.
A team of researchers has conducted a comprehensive analysis of genomic variation in glioblastoma, the most common and aggressive primary brain tumor. The study's findings highlight the importance of integrating genomic and epigenomic measurements to better understand cancer genetics.
The Cancer Genome Atlas identifies new genetic mutations, including NF1, ERBB2, and PIK3R1, and core pathways disrupted in glioblastoma. The study provides an unprecedented overview of the genomic landscape of this deadly cancer.
Researchers have discovered a mechanism to overcome the resistance of human glioblastoma multiforme cells to growth factor inhibitors by blocking inhibitor of apoptosis proteins. Combining drugs targeting IAPs with RTK inhibitors showed enhanced efficacy in inhibiting tumor growth. Additionally, targeting liver CB1 receptors may provid...
Researchers found that RTK inhibitors can be less effective in treating glioblastoma multiforme (GBM) due to cell death inhibition. Combining RTK and IAP inhibitors showed promise in inducing apoptosis in GBM cells, with enhanced efficacy in orthotopic mouse models.
A new vaccine targets glioblastoma multiforme, doubling survival time and more than quadrupling progression-free survival. The vaccine has caused virtually no side effects, making it a promising therapy for this deadly brain tumor.
A new vaccine targeting human cytomegalovirus (CMV) shows promise in delaying the recurrence of deadly brain tumors, glioblastoma multiforme (GBM). The study found that patients receiving the vaccine experienced a significant delay in tumor regrowth, with overall survival extended to over 20 months.
The Novo-TTF device demonstrated significant efficacy in reducing tumor volume and improving outcomes for patients with locally advanced breast cancer. The device's non-invasive technology disrupts cancer cell proliferation, offering a potential alternative to traditional chemotherapy.
Researchers have validated genetic aberrations and identified new targets for GBM treatment. A novel regulatory circuit involving INK4 family genes, p18INK4C and p16INK4A, constrains inappropriate glial cell proliferation and enhances tumorigenicity.
Researchers found that CD95 on glioblastoma cells is activated by CD95L, leading to the production of MMP9, which cuts through tissue layers and allows cancer cells to invade healthy tissue. Blocking this activation may be a new approach to stopping glioblastoma's spread.
Researchers developed gene therapy approach that attracts and 'trains' immune system cells to destroy deadly brain cancer cells, promoting long-term immunity and restoring normal brain function. The therapy shows promise as a potential treatment for glioblastoma multiforme, the most common and deadly type of brain cancer.
Researchers found that STAT3 has tumor-promoting and tumor-suppressing effects depending on the genetic profile of glioblastoma tumors. This discovery highlights the need for effective therapies tailored to individual glioblastoma tumors.
A study published in the Journal of Neurosurgery found that simultaneous implantation of radioactive seeds and chemotherapy wafers following surgery improved patient survival rates for recurrent glioblastoma multiforme (GBM) patients. The median survival was 69 weeks, with nearly a quarter of patients surviving two years.
Researchers developed a three-drug cocktail targeting glioblastoma multiforme tumors, which showed significant benefits in killing cancer cells and sparing healthy brain tissue. The treatment is based on the first-ever documented molecular signature of GBM tumors and may be tested in patients within five years.
A clinical study at Henry Ford Hospital found that Avastin significantly extended the survival of patients with glioblastoma multiforme, with over half living without disease progression for six months. The use of Avastin also showed no new adverse effects.
Researchers found that patients with glioblastoma multiforme treated with radiation and chemotherapy drug temozolomide can live up to four years after diagnosis, compared to three percent of those who received only radiation. The treatment has become the standard for GBM patients worldwide.
A new study found that a combination of bevacizumab (Avastin) and chemotherapy may increase survival time for patients with glioblastoma multiforme, a deadly type of brain tumor. The treatment showed promising results in improving outcomes for patients who have already been diagnosed with the disease.
MIT scientists have discovered a connection between two proteins found in brain tumors that could help treat glioblastoma multiforme (GBM), the most aggressive form of brain cancer. Attacking both EGFRvIII and c-Met simultaneously is more effective than targeting either protein alone, offering new hope for treating this deadly disease.
Researchers found vorinostat's anti-cancer activity in patients with recurrent glioblastoma multiforme, with a 15% patient success rate and improved median overall survival. The study aimed to explore the novel application of vorinostat in targeting brain cancer.
The Novo-TTF device has been shown to disrupt tumor growth by interfering with cell division of cancerous cells, causing them to stop proliferating and die off. In a pilot trial, 10 patients with recurring GBM experienced improved survival rates, with median overall survival doubling compared to historical data.
Researchers have discovered a new class of genetic mutations in the EGFR gene that occur in glioblastoma, a deadly type of brain tumor. These mutations, located in the extracellular domain of the protein, can activate oncogenically EGFR, making them a potential target for cancer therapy.
Mayo Clinic Cancer Center is conducting a clinical study using a vaccine strain of the measles virus to treat recurrent glioblastoma multiforme, a deadly brain tumor. The study has shown promising results in shrinking tumors and prolonging animal survival.
Gliadel Wafer demonstrates long-term survival benefit for patients with high-grade malignant glioma, increasing median survival to 13.9 months from 11.6 months. The treatment also shows a significant reduction in risk of death over the study period, with a 27% lower risk compared to placebo.
Glioblastoma multiforme, the most common adult brain cancer, has a median survival of about one year after diagnosis. Researchers have identified EGFR as a target for therapeutic drugs, offering new hope for patients. The study found that targeting both mutant and normal EGFR can destroy brain cancer cells while sparing healthy ones.
Researchers have discovered a new radiotherapy technique using gadolinium to treat glioblastoma (GBM) with minimal invasiveness. The therapy, called Gadolinium Synchrotron Stereotactic Radiotherapy (GdSSR), targets cancer cells while sparing normal brain tissue, offering a potential cure for this deadly disease.
Researchers identified EGFRvIII and PTEN proteins as key factors in determining tumor response to EGFR inhibitors. These findings suggest that adjusting treatment based on genetic activity could significantly prolong life for glioblastoma patients and prevent unnecessary treatments.
Researchers at UCLA have identified a molecular signature that can predict which patients with glioblastoma, a deadly brain cancer, are likely to respond to drug therapy. The discovery involves the presence of a mutant protein and a tumor suppressor protein called PTEN.
Researchers developed a large brain tumor model and tested a genetically engineered virus delivering two proteins to the brain. The findings show that combined RAdTK and RAdFlt3L gene therapy eliminated glioblastoma multiforme in lab rats, increasing survival rates significantly.
Researchers at Mayo Clinic have developed a new treatment for recurrent glioblastoma multiforme, a form of adult brain cancer with dismal prognosis. The 'smart' drug CCI-779 showed significant response in 36 percent of patients, suggesting potential improvement in treatment outcomes.
A study of 301 patients with glioblastoma multiforme found that the 'SS' variant genotype of hTERT significantly improved survival rates, averaging 25 months compared to 14 months for other genotypes. The research suggests new treatment directions for this aggressive cancer.
Researchers at Cedars-Sinai Medical Center found that a genetically engineered virus delivering the protein hsFlt3L slowed tumor growth and increased immune cell production in laboratory rats with glioblastoma multiforme. The study may lead to a new treatment approach for patients with GBM.